Jonathan has a successful track record of raising Seed and Series A funding in aggregate of $160M from venture capital, strategic and private investors, and non-dilutive sources incl. the Bill and Melinda Gates Foundation, the Department of Defense, the National Institutes of Health, ARPA-H and BARDA. He has demonstrated strategic and operational leadership ability in defining, communicating, and scaling ambitious technical visions for innovative, high-growth startups.

Jonathan is a seasoned inspirational executive who excels at securing new financing, IP creation, and building high performance management teams and collaborative research environments.

 

Jonathan has served as Founder/CEO of:

STRM.BIO, the first gene delivery platform capable of completely bypassing the liver to target long-term hematopoietic stem cells in vivo.

Stellular Bio (formerly Platelet Biogenesis), responsible for the first functional human platelets from iPSC culture to treat hematological and oncological diseases.

Jonathan was an Assistant Professor at Brigham & Women’s Hospital and Harvard Medical School, where he established cell culture and microfluidic programs in hematology and oncology, and guided dozens of students toward rewarding careers in medicine and biopharma.

Jonathan earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia and completed his postdoctoral research fellowship in hematology at Harvard Medical School.